Core Viewpoint - The Virginia Workers' Compensation Commission has affirmed that an employee of Abbott Laboratories is entitled to workers' compensation benefits for a cervical spine injury sustained while performing a common courtesy during a company event, despite the employer's claims that the action was outside the scope of employment [2][3][10]. Group 1: Incident Details - The employee was injured while attempting to move her manager's heavy backpack during a national sales conference [2]. - The backpack contained work-related items, including a laptop and personal notebooks, which the deputy commissioner noted were relevant to the employee's duties [4]. - The employer acknowledged the injury but contested the compensation, arguing that the employee was not expected to handle the manager's belongings [5][6]. Group 2: Employer's Arguments - The employer claimed that handling personal belongings was not part of the employee's job responsibilities and questioned the risk of theft or loss at a secure company event [6][7]. - They argued that the employee could have injured herself in any context, not just in relation to her employment [7]. - The employer's assertion that the action was not a risk associated with employment was rejected by the commission [11]. Group 3: Commission's Ruling - The VWCC found that the employee's actions were incidental to her employment, emphasizing that the voluntary nature of the action does not negate the claim for injury [9][10]. - The commission clarified that an accident occurs in the course of employment if it happens during work hours and at a location where the employee is expected to be [10]. - The commission concluded that the injury arose from a significant work-related exertion, affirming the connection to the employee's employment [11].

Group 1 - AstraZeneca plans to establish a cell therapy manufacturing and supply base along with an innovation center in Shanghai, aiming to be the first global drugmaker with comprehensive cell therapy capabilities in China [1][2] - The new facility will focus on the production and supply of autologous CART cell therapies for China and other Asian markets [2]

RT Tehran Times (@TehranTimes79)#BREAKINGTajikistan sent pharmaceutical, medical, hygiene, food and construction materials aid to Iran https://t.co/VSgbOPFKOX ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Background - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" when, in fact, the FDA had raised concerns about the clinical evidence [5]. - Throughout the Class Period, Corcept's management expressed confidence in the NDA approval process, stating that "relacorilant is approaching approval," despite known risks regarding the NDA's adequacy [5].

Core Insights - Protagonist Therapeutics, Inc. has received a "Buy" rating upgrade from Jefferies, with the stock priced at $97.78 at the time of the upgrade [1][6] - The U.S. FDA has approved ICOTYDE™ (icotrokinra), marking a significant milestone as it is the first oral peptide targeting IL-23R for treating moderate-to-severe plaque psoriasis in both adults and children aged 12 and older [2] - The FDA's approval is based on four phase 3 studies involving 2,500 patients, all meeting primary endpoints and demonstrating a favorable safety profile, triggering a $50 million milestone payment for the company [3] Stock Performance - Following the FDA approval, PTGX's stock price slightly decreased by 0.14% to $97.09, despite the positive news [4][6] - The stock has fluctuated between $90.58 and $99.44 recently, with a one-year high of $99.45 and a low of $39.60, and a market capitalization of approximately $6.2 billion [4] Future Prospects - Protagonist Therapeutics is set to receive 6% to 10% royalties on sales of ICOTYDE and up to $580 million in future milestone payments [3] - The company plans to discuss the recent developments in a webcast and conference call scheduled for March 18 [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable ranking by ISS Securities Class Action Services [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in clinical trials for Osteogenesis Imperfecta, leading to inflated stock prices [5][6]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to management's assertions [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making materially false statements regarding its Phase 3 clinical trial program for its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [2][5][6]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its only commercial product is diazoxide choline extended-release tablets (DCCR) [4]. Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, with the case captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., et al, Case No. 3:26-cv-01979 (N.D. Cal.) [2]. - Investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, are eligible to seek lead plaintiff status by May 5, 2026 [2][8]. Allegations - The complaint alleges that Soleno's executives misrepresented and failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [5]. - It is claimed that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and potential adverse events post-launch [5]. - The lawsuit highlights that the company's statements regarding its business and operations were materially false and misleading throughout the class period [5]. Stock Performance - Following the release of financial results on November 4, 2025, and a report by Scorpion Capital, Soleno's stock price dropped over 26%, attributed to concerns raised about the DCCR launch trajectory and clinical trial issues [6][7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The lawsuit claims that Ultragenyx provided misleading information regarding the efficacy of setrusumab in reducing fracture rates in Osteogenesis Imperfecta patients, leading to inflated stock prices [5][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in securities class action settlements since 2013 [4]. Group 3: Case Specifics - The lawsuit alleges that Ultragenyx's positive statements about setrusumab's potential were misleading, as the increase in bone density did not correlate with a decrease in fracture rates, contrary to what was claimed [6].

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who purchased Corcept Therapeutics Incorporated (CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding the viability of its new product candidate, relacorilant [1][2]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol effects [1]. Allegations - The class action alleges that Corcept misrepresented the clinical trials supporting relacorilant as a treatment for hypercortisolism, claiming they provided "powerful support" for the New Drug Application (NDA) submitted to the FDA [2]. - Defendants stated they had communicated with the FDA and were confident in the NDA submission, foreseeing no impediments to approval, while the FDA had raised concerns about the adequacy of clinical evidence [2]. Impact of FDA Response - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the NDA of relacorilant, stating that additional evidence of effectiveness was required [3]. - Following this announcement, Corcept's stock price fell from $70.20 on December 30, 2025, to $34.80 on December 31, 2025, representing a decline of 50.4% [3]. Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].

Core Viewpoint - Aldeyra Therapeutics, Inc. experienced a significant decline in stock value, losing approximately 70% of its holdings after the FDA issued a Complete Response Letter for reproxalap, citing insufficient efficacy for treating dry eye disease [1]. Group 1: Regulatory and Clinical Developments - Aldeyra's management had previously made optimistic public statements regarding reproxalap's clinical profile and regulatory path, which were contradicted by the FDA's findings [2]. - The FDA's Complete Response Letter, issued on March 17, 2026, indicated that the New Drug Application (NDA) for reproxalap did not demonstrate sufficient efficacy, contrary to the company's earlier assertions [2]. Group 2: Legal Implications - Levi & Korsinsky is investigating whether Aldeyra Therapeutics made misleading statements regarding reproxalap's efficacy data and regulatory prospects, which may have contributed to investor losses [3]. - Investors who purchased ALDX shares and suffered losses are encouraged to explore their legal rights regarding potential class action claims [3].